Código QR

LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition

Abstract Background Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide. Sorafenib is commonly used as first-line systemic treatment for advanced HCC, but the clinical benefits fall victim to either primary or acquired drug resistance. Modulating f...

Descrición completa

Gardado en:
Principais autores: Jiunn-Chang Lin, Tun-Sung Huang, Yan-Bin Chen, Tung-Ying Chen, Pao-Shu Wu, Tsang-Pai Liu, Pei-Ming Yang
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2026-02-01
Series:Biology Direct
Assuntos:
LDN-57444
Sorafenib
Hepatocellular carcinoma
Ferroptosis
HDAC2
Acceso en liña:https://doi.org/10.1186/s13062-026-00735-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares